Nerve growth factor receptor (p75NTR) and pattern of invasion predict poor prognosis in oral squamous cell carcinoma

Histopathology

Volumn 53, Issue 1, 2008, Pages 62-72

  Soland T M ^a,b   Brusevold, I J ^b   Koppang, H S ^a   Schenck, K ^b   Bryne, M ^b  

^a Oral Research Laboratory   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

Immunohistochemistry; Invasive front; Invasive front grading; NGFR; Oral cancer; p75NTR; Prognostic markers

Indexed keywords

NEUROTROPHIN RECEPTOR P75;

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER RECURRENCE; CANCER SURVIVAL; CANCER TISSUE; CELL INVASION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LOG RANK TEST; MALE; MOUTH CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; RECURRENCE RISK; SQUAMOUS CELL CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; MOUTH NEOPLASMS; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NERVE TISSUE PROTEINS; PROSPECTIVE STUDIES; RECEPTORS, NERVE GROWTH FACTOR; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 45549096063     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2008.03063.x     Document Type: Article

References (43)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int. J. Cancer 2001 94 153 156.
2. Parkin DM, Bray F, Ferlay J, Pisani P. Global Cancer Statistics, 2002. CA Cancer J. Clin. 2005 55 74 108.
3. Epstein J. Oral cancer. In Lynch MA, Brightman VT, Greenberg MS eds. Burket's oral medicin. Philadelphia, PA:J.B. Lippincott Co, 1994 203 239.
4. Braakhuis BJM, Brakenhoff RH, Leemans CR. Second field tumors: a new opportunity for cancer prevention? Oncologist 2005 10 493 500.
5. Roux PP, Barker PA. Neurotrophin signaling through the p75 neurotrophin receptor. Prog. Neurobiol. 2002 67 203 233.
6. Nykjaer A, Willnow TE, Petersen CM. p75NTR - live or let die. Curr. Opin. Neurobiol. 2005 15 49 57.
7. Hempstead BL. The many faces of p75NTR. Curr. Opin. Neurobiol. 2002 12 260 267.
8. Arévalo JC, Wu SH. Neurotrophin signaling: many exciting surprises. Cell. Mol. Life Sci. 2006 63 1523 1537.
9. Gentry JJ, Barker PA, Carter BD. The p75 neurotrophin receptor: multiple interactors and numerous functions. In Aloe L, Calza L eds. NGF and related molecules in health and diseas. Amsterdam:Elsevier Science, 2004 25 39.
10. Thompson SJ, Schatteman GC, Gown AM, Bothwell M. A monoclonal antibody against nerve growth factor receptor. Immunohistochemical analysis of normal and neoplastic human tissue. Am. J. Clin. Pathol. 1989 92 415 423.
11. Fanburg-Smith JC, Miettinen M. Low-affinity nerve growth factor receptor (p75) in dermatofibrosarcoma protuberans and other nonneural tumors: A study of 1,150 tumors and fetal and adult normal tissues. Hum. Pathol. 2001 32 976 983.
12. Hayashi K, Storesund T, Schreurs O et al. Nerve growth factor β/pro-nerve growth factor and their receptors in normal human oral mucosa. Eur. J. Oral Sci. 2007 115 344 354.
13. Rocha AS, Risberg B, Magalhaes J et al. The p75 neurotrophin receptor is widely expressed in conventional papillary thyroid carcinoma. Hum. Pathol. 2006 37 562 568.
14. Okumura T, Tsunoda S, Mori Y et al. The biological role of the low-affinity p75 neurotrophin receptor in esophageal squamous cell carcinoma. Clin. Cancer Res. 2006 12 5096 5103.
15. Davidson B, Reich R, Lazarovici P, Flørenes V, Nielsen S, Nesland J. Altered expression and activation of the nerve growth factor receptors TrkA and p75 provide the first evidence of tumor progression to effusion in breast carcinoma. Breast Cancer Res. Treat. 2004 83 119 128.
16. Davidson B, Lazarovici P, Ezersky A et al. Expression levels of the nerve growth factor receptors TrkA and p75 in effusions and solid tumors of serous ovarian carcinoma patients. Clin. Cancer Res. 2001 7 3457 3464.
17. Krygier S, Djakiew D. Neurotrophin receptor p75(NTR) suppresses growth and nerve growth factor-mediated metastasis of human prostate cancer cells. Int. J. Cancer 2002 98 1 7.
18. Marchetti D, Aucoin R, Blust J, Murry B, Greiter-Wilke A. p75 neurotrophin receptor functions as a survival receptor in brain-metastatic melanoma cells. J. Cell. Biochem. 2004 91 206 215.
19. Rabizadeh S, Bredesen DE. Ten years on: mediation of cell death by the common neurotrophin receptor p75NTR. Cytokine Growth Factor Rev. 2003 14 225 239.
20. Rabizadeh S, Oh J, Zhong LT et al. Induction of apoptosis by the low-affinity NGF receptor. Science 1993 261 345 348.
21. Dang C, Zhang Y, Ma Q, Shimahara Y. Expression of nerve growth factor receptors is correlated with progression and prognosis of human pancreatic cancer. J. Gastroenterol. Hepatol. 2006 21 850 858.
22. Zhang Y, Dang C, Ma Q, Shimahara Y. Expression of nerve growth factor receptors and their prognostic value in human pancreatic cancer. Oncol. Rep. 2005 14 161 171.
23. Walch ET, Albino AP, Marchetti D. Correlation of overexpression of the low-affinity p75 neurotrophin receptor with augmented invasion and heparanase production in human malignant melanoma cells. Int. J. Cancer 1999 82 112 120.
24. Herrmann JL, Menter DG, Hamada J, Marchetti D, Nakajima M, Nicolson GL. Mediation of NGF-stimulated extracellular matrix invasion by the human melanoma low-affinity p75 neurotrophin receptor: melanoma p75 functions independently of trkA. Mol. Biol. Cell 1993 4 1205 1216.
25. Bryne M, Koppang HS, Lilleng R, Stene T, Bang G, Dabelsteen E. New malignancy grading is a better prognostic indicator than Broders' grading in oral squamous cell carcinomas. J. Oral Pathol. Med. 1989 18 432 437.
26. Bryne M, Boysen M, Alfsen C et al. The invasive front of carcinomas. The most important area for tumour prognosis? Anticancer Res. 1998 18 4757 4764.
27. Bhowmick NA, Moses HL. Tumor-stroma interactions. Curr. Opin. Genet. Dev. 2005 15 97 101.
28. Liotta LA, Kohn EC. The microenvironment of the tumour-host interface. Nature 2001 411 375 379.
29. Bankfalvi A, Piffko J. Prognostic and predictive factors in oral cancer: the role of the invasive tumour front. J. Oral Pathol. Med. 2000 29 291 298.
30. Schliephake H. Prognostic relevance of molecular markers of oral cancer - a review. Int. J. Oral Maxillofac. Surg. 2003 32 233 245.
31. Harmer M. TNM classification of malignant tumors. Geneva:International Union Against Cancer, 1987.
32. Pindborg JJ, Reichart PA, Smith CJ, van der Waal I. Histological typing of cancer and precancer of the oral mucosa, World Health Organization international histological classification of tumours. Berlin:Springer-Verlag, 1997.
33. Yamamoto E, Kohama G, Sunakawa H, Iwai M, Hiratsuka H. Mode of invasion, bleomycin sensitivity, and clinical course in squamous cell carcinoma of the oral cavity. Cancer 1983 51 2175 2180.
34. Christofori G. New signals from the invasive front. Nature 2006 441 444 450.
35. Lee JM, Dedhar S, Kalluri R, Thompson EW. The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J. Cell Biol. 2006 172 973 981.
36. Piffko J, Bankfalvi A, Ofner D et al. Prognostic value of histobiological factors (malignancy grading and AgNOR content) assessed at the invasive tumour front of oral squamous cell carcinomas. Br. J. Cancer 1997 75 1543 1546.
37. Welkoborsky HJ, Hinni M, Dienes HP, Mann WJ. Predicting recurrence and survival in patients with laryngeal-cancer by means of DNA cytometry, tumor front grading, and proliferation markers. Ann. Otol. Rhinol. Laryngol. 1995 104 503 510.
38. Odell EW, Jani P, Sherriff M et al. The prognostic value of individual histologic grading parameters in small lingual squamous-cell carcinomas - the importance of the pattern of invasion. Cancer 1994 74 789 794.
39. Bryne M, Jenssen N, Boysen M. Histological grading in the deep invasive front of T1 and T2 glottic squamous cell carcinomas has high prognostic value. Virchows Arch. 1995 427 277 281.
40. Bundgaard T, Rossen K, Henriksen SD, Charabi S, Søgaard H, Grau C. Histopathologic parameters in the evaluation of T1 squamous cell carcinomas of the oral cavity. Head Neck 2002 24 656 660.
41. Descamps S, Toillon RA, Adriaenssens E et al. Nerve growth factor stimulates proliferation and survival of human breast cancer cells through two distinct signaling pathways. J. Biol. Chem. 2001 276 17864 17870.
42. Khwaja F, Tabassum A, Allen J, Djakiew D. The p75NTR tumor suppressor induces cell cycle arrest facilitating caspase mediated apoptosis in prostate tumor cells. Biochem. Biophys. Res. Commun. 2006 341 1184 1192.
43. El Yazidi-Belkoura I, Adriaenssens E, Dolle L, Descamps S, Hondermarck H. Tumor necrosis factor receptor-associated death domain protein is involved in the neurotrophin receptor-mediated antiapoptotic activity of nerve growth factor in breast cancer cells. J. Biol. Chem. 2003 278 16952 16956.